SCHEMBL6329709

SCHEMBL6329709

COC(=O)C(=O)c1c[nH]c2c(C(C)C(=O)O)cccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 3/20 0.47
HAT1 O14929 1/20 0.43
EP300 Q09472 1/20 0.43
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
BRPF1 P55201 1/20 0.40
UBE2N P61088 1/20 0.38
CREBBP Q92793 1/20 0.38
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
CXCL8 P10145 1/20 0.36
ALOX5 P09917 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
CASP3 P42574 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6029455 0.82 NR4A2 (0.45) NR4A2HAT1EP300ALDH1A1KDM4E
SCHEMBL989756 0.79 NR4A2 (0.73) NR4A2HAT1EP300ALDH1A1KDM4E
SCHEMBL6029970 0.78 NR4A2 (0.51) NR4A2ALDH1A1KDM4EHPGDBRPF1
SCHEMBL7210602 0.78 NR4A2 (0.51) NR4A2BRPF1RAB9A
SCHEMBL6029339 0.78 ALDH1A1 (0.62) NR4A2HAT1EP300ALDH1A1KDM4E
SCHEMBL14486971 0.78 NR4A2 (0.62) NR4A2ALDH1A1KDM4EHPGDBRPF1
SCHEMBL4802347 0.75 CLEC4M (0.48) NR4A2HAT1EP300ALDH1A1KDM4E
SCHEMBL6329279 0.75 NR4A2 (0.48) NR4A2ALDH1A1KDM4EHPGDBRPF1
SCHEMBL12748340 0.74 HAT1 (0.49) NR4A2HAT1EP300ALDH1A1KDM4E
SCHEMBL31023147 0.74 HAT1 (0.49) NR4A2HAT1EP300ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867198-B2 Agents and methods for the treatment of proliferative diseases ELI LILLY AND COMPANY (US) 2005-03-15 US disclosed
US-20030229026-A1 Agents and methods for the treatment of proliferative diseases ELI LILLY AND COMPANY 2003-12-11 US disclosed
EP-1242420-A2 AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2002-09-25 EP disclosed
WO-2001044247-A2 AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229026-A1 Agents and methods for the treatment of proliferative diseases MKI67, CDKN1A, CDK1 NR4A2 2139/4885HAT1 1676/4885EP300 1174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.